

Risk factors for short term thyroid dysfunction after hematopoietic stem cell transplantation in children

You Jin Jung, MD, Yeon Jin Jeon, MD, Won Kyoung Cho, MD, Jae Wook Lee, MD, Nack-Gyun Chung, MD, Min Ho Jung, MD, Bin Cho, MD, Byung-Kyu Suh, MD

Department of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea

Purpose: The purpose of this study was to evaluate short-term thyroid dysfunction and related risk factors in pediatric patients who underwent hematopoietic stem cell transplantation (HSCT) during childhood.

Methods: We studied 166 patients (100 boys and 66 girls) who underwent HSCT at the Catholic HSCT Center from January 2004 through December 2009. The mean age at HSCT was 10.0 ± 4.8 years. Thyroid function of the patients was tested before and during 3 months of HSCT.

Results: Out of 166 patients, 165 (99.4%) underwent allotransplantation. Acute graft-versus-host disease (GVHD, grades II to IV) developed in 76 patients. Conditioning regimens before HSCT include total body irradiation (n=57), busulfan (n=80), and reduced intensity (n=29). Forty-five (27.1%) had thyroid dysfunction during 3 months after HSCT (29 euthyroid sick syndrome [ESS], 6 subclinical hyperthyroidism, 4 subclinical hypothyroidism, 3 hypothyroxinemia, 2 overt hyperthyroidism, and 1 high T_4 syndrome). In a univariate logistic regression analysis, age at HSCT ($P=0.002$) and acute GVHD ($P=0.009$) had statistically significant relationships with thyroid dysfunction during 3 months after HSCT. Also, in a univariate logistic regression analysis, ESS ($P=0.014$) showed a strong statistically significant association with mortality.

Conclusion: In our study 27.1% patients experienced thyroid dysfunction during 3 months after HSCT. Increase in age and acute GVHD may be risk factors for thyroid dysfunction during 3 months after HSCT. There was a significant association between ESS and mortality.

Key words: Hematopoietic stem cell transplantation, Thyroid dysfunction, Child, Graft-vs-host disease, Euthyroid sick syndrome

Corresponding author: Byung-Kyu Suh, MD
Department of Pediatrics, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea

Tel: +82-2-2258-6185

Fax: +82-2-532-6185

E-mail: suhbk@catholic.ac.kr

Received: 14 September, 2012

Revised: 12 October, 2012

Accepted: 23 October, 2012

Introduction

Hematopoietic stem cell transplantation (HSCT) after intensive chemotherapy or radiation therapy has become an important therapeutic modality for hematologic malignancy, malignant tumors, aplastic anemia, and congenital and acquired immune diseases¹. HSCT has improved the prognosis of children with malignant or nonmalignant hematologic disease. However, it has had significant adverse effects on the endocrine system, including thyroid, pituitary, and gonadal dysfunction^{2,3}. Subclinical hypothyroidism and overt hypothyroidism are common long-term thyroid dysfunctions after HSCT^{2,4-8}; thyroid tumors were reported in a smaller number of patients^{5,6}.

Relevant previous studies have mostly focused on long-term thyroid dysfunction after HSCT^{2,4,6,7,9}; only a few have focused on short-term changes. Euthyroid sick syndrome

Copyright © 2013 by The Korean Pediatric Society

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

(ESS) was reported to be the most common short-term thyroid dysfunction^{3,10}. However, there is no study on the frequency, progress, and risk factors of short-term thyroid dysfunction. We investigated risk factors for thyroid dysfunction during 3 months after HSCT in childhood.

Materials and methods

1. Patients selection and GVHT grading

Out of 214 patients, 166 (100 females and 66 males) were included in the study. These patients had undergone HSCT at Seoul St. Mary's Hospital HSCT Center at the Catholic University of Korea from January 2004 through December 2009. Patients who were not

evaluated for thyroid function (n=3), those with abnormal thyroid function before transplantation (n=28), those with solid tumor (n=13), and those who died within 3 months after HSCT (n=4) were excluded from the study. Patients underwent HSCT for malignant and nonmalignant hematological diseases (43 acute lymphoblastic leukemia, 79 acute myeloid leukemia, 8 chronic myelogenous leukemia, 31 aplastic anemia, 5 Fanconi anemia, 3 hemophagocytic lymphohistiocytosis). Twenty-one patients with acute lymphoblastic leukemia underwent transplantation after first complete remission and 22 patients underwent transplantation after second complete remission. Seventy-one patients with acute myeloid leukemia underwent transplantation after first complete remission, and 5 underwent transplantation after second complete remission. All 8 chronic myelogenous leukemia patients underwent transplantation after the first chronic phase (Table 1).

A grading system designed by Glucksberg in 1974 and modified by Keystone in 1994 was used to grade acute graft-versus-host disease (GVHD) according to the organs involved: skin, liver, and gastrointestinal tract¹¹. The patients were suspected to have acute GVHD when the following symptoms manifested within the first 100 days after HSCT: skin rashes, blisters, excruciating abdominal pain with or without diarrhea, constant nausea and vomiting, and hepatitis (increase in bilirubin and liver enzyme levels). Seventy-six patients exhibited acute GVHD, grade II to IV, after HSCT.

2. Methods

Transplantation donors were patients themselves (n=1), siblings (n=36), and unrelated persons (n=129). The cell sources were bone marrow (n=68), peripheral blood (n=81), and cord blood (n=17)

Table 1. Patient characteristics and treatment variables

Characteristic	Value
Age at HSCT (yr)	10.0±4.8
Sex	
Male	100 (60.2)
Female	66 (39.8)
Lymphoid (acute lymphoblastic leukemia)	43 (25.9)
First complete remission	21 (48.8)
Second complete remission	22 (51.2)
Myeloid	84 (50.6)
Acute myeloid leukemia	76 (90.5)
First complete remission	71 (93.4)
Second complete remission	5 (6.6)
Chronic myelogenous leukemia	8 (9.5)
First chronic phase	8 (100.0)
Nonmalignant	39 (23.5)
Severe aplastic anemia	31 (79.5)
Fanconi anemia	5 (12.8)
Hemophagocytic lymphohistiocytosis	3 (7.7)
Type of stem cell transplantation	
Autologous	1 (0.6)
Allogeneic	165 (99.4)
Sibling	36 (21.8)
Unrelated	129 (78.2)
Cell source	
Bone marrow	68 (41.0)
Peripheral blood stem cell	81 (48.8)
Cord	17 (10.2)
Acute graft-versus-host disease	
0-I	90 (54.2)
II-IV	76 (45.8)

Values are presented as mean±standard deviation or number (%). HSCT, hematopoietic stem cell transplantation; Unrelated, unrelated matched.

Table 2. Preparative regimens for hematopoietic stem cell transplantation of 166 patients

Preparative regimens	No. of patients (%)
TBI-based	57 (34.3)
CY+TBI*	8 (14.0)
CY+ARA+TBI†	41 (71.9)
CY+Flu+ATG+TBI‡	8 (14.0)
BU-based	80 (48.2)
BU+CY§	41 (51.3)
BU+Flu	39 (48.7)
Reduced intensity conditioning	29 (17.5)
CY+ATG+procarbazine¶	7 (24.1)
CY+Flu+ATG	22 (75.9)

TBI, total body irradiation 1,200 cGy, 200 Gy/fraction, 2 fractions/day for 3 days; CY, cyclophosphamide; ARA, anthracycline; ATG, antithymocyte globulin; Flu, fludarabine; BU, busulfan; VP, Vepesid.

*CY 60 mg/kg for 2 days+TBI. †CY 60 mg/kg for 2 days+ARA 3 g/m² twice per day for 2 days+TBI. ‡CY 50 mg/kg for 4 days+Flu 30 mg/m² for 6 days+ATG 1 V/20 kg for 3 days+TBI. §CY 60 mg/kg for 2 days+BU 0.8 mg/kg for 4 days. ||BU 130 mg/m² for 4 days+Flu 40 mg/m² for 4 days. ¶CY 50 mg/kg for 4 days+ATG 1 V/20 kg for 3 days+procarbazine 12.5 mg/kg for 3 days.

(Table 1). Preconditioning for transplantation was carried out according to the underlying diseases and the protocol used at the time of transplantation. Preconditioning regimens were classified according to the type of total body irradiation (TBI; 1,200 cGy, n=57), busulfan (n=80), and reduced intensity (n=29). Specifics of the conditioning regimen are outlined in Table 2.

Thyroid function was tested before and 3 months (averaging from 70 to 110 days after HSCT) after transplantation to assess thyroid-stimulating hormone (TSH), total triiodothyronine (T₃), total thyroxine (T₄), and free thyroxine (fT₄). Serum was separated from obtained blood samples, and hormone levels were checked by radioimmune assay. Automated instrument (AdviaCentaur, Siemens, Germany) was used for the assessment of TSH, T₃, T₄, and fT₄.

The normal reference value of T₃ was 0.8 to 2.1 ng/mL; free T₄ was 0.8 to 2.2 ng/dL; T₄ was 3.2 to 12.5 ng/dL; and TSH was 0.17 to 6.0 mIU/L. Diagnoses were based on the results of the thyroid function test and were as follows:

Cases with normal fT₄ and TSH but decreased T₃, or normal fT₄ with decreased TSH and T₃ were diagnosed as ESS^{12,13}. Cases with only decreased TSH were diagnosed as subclinical hyperthyroidism. Cases with normal T₃ and free T₄ but TSH greater than 6 mIU/L were diagnosed as subclinical hypothyroidism. Cases with only decreased fT₄ or T₄ were diagnosed as hypothyroxemia. Cases with increased TSH and reduced fT₄ were diagnosed as overt hypothyroidism. In addition, high T₄ syndrome was diagnosed when only fT₄ or T₄ was increased^{12,13} (Table 3).

3. Statistical analysis

Descriptive Statistics are used to describe the clinical and treatment factors of patients. Values are expressed as mean± standard deviation. Univariate logistic regression analyses were performed to assess the risk factors that are considered to exert effects on thyroid dysfunction and the association between ESS during 3 months after HSCT and mortality. *P* values <0.05 were considered to be statistically significant. SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses.

Results

1. Thyroid dysfunction during 3 months after HSCT

Compared with pre-HSCT data, test results 3 months after HSCT showed thyroid dysfunction in 45 patients (27.1%). Among the patients who showed thyroid dysfunction, 29 (64.4%) were ESS, 6 (13.3%) had subclinical hyperthyroidism, 4 (8.9%) had subclinical hypothyroidism, 3 (6.7%) had hypothyroxemia, 2 (4.5%) had overt hypothyroidism, and 1 (2.2%) had high T₄ syndrome (Table 3).

2. Risk factors for thyroid dysfunction during 3 months after HSCT

According to univariate analysis, increase in age (*P*=0.002) and grade II acute GVHD or above (*P*=0.009) were significantly associated with thyroid dysfunction during 3 months after HSCT. The incidence of thyroid dysfunction showed no relationship with sex, underlying diseases or TBI in preconditioning regimen (Table 4).

3. Analysis of death after HSCT

The mean duration of follow-up was 5.9 years, ranging from 2.7 to 8.7 years. Among 166 patients, 48 patients died within average of 11 months. Cause of death was pneumonia (n=23), sepsis (n=12), GVHD (n=8), organ failure (n=3) and unknown (n=2).

Table 3. Distribution of thyroid dysfunction

Thyroid dysfunction*	No. (n=45)
Euthyroid sick syndrome	29
Overt hyperthyroidism	2
Hypothyroxinemia	3
Subclinical hyperthyroidism	6
Subclinical hypothyroidism	4
High T ₄ syndrome	1

*During 3 months after hematopoietic stem cell transplantation.

Table 4. Risk factors associated with thyroid dysfunction during 3 months after HSCT

Factor	Univariate logistic	
	OR (95% CI)	<i>P</i> value*
Age at HSCT	1.134 (1.046–1.230)	0.002
Sex		0.500
Male	1.000	
Female	0.783 (0.385–1.593)	
Diagnosis		0.183
Nonmalignant	1.000	
Lymphoid	2.383 (0.804–7.063)	
Myeloid	2.466 (0.921–6.604)	
Conditioning		0.569
Non-TBI based	1.000	
TBI based	1.229 (0.603–2.505)	
aGVHD grade		0.009
0–I	1.000	
II–IV	2.589 (1.266–5.292)	

OR, odds ratio; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; TBI, total body irradiation; aGVHD, acute graft-versus-host disease.

**P*<0.05.

4. Relationship between mortality rate and incidence of ESS occurring 3 months after HSCT

According to univariate analysis, mortality rate after HSCT was significantly higher in patients with ESS during 3 months after HSCT ($P=0.014$) as compared to the non-ESS group. Age ($P=0.309$) and grade of acute GVHD ($P=0.080$) showed no significant relationship with mortality (Table 5).

5. Risk factors for ESS occurring 3 months after HSCT

According to univariate analysis, the incidence rate of ESS was significantly higher in older children ($P=0.006$) and patients with acute GVHD of grade II or above ($P=0.002$). No statistical significance was shown between underlying diseases and pre-

conditioning regimen (Table 6).

Discussion

One of the most remarkable advances in modern medicine is the progress made in the field of transplantation technology, which has improved the survival rate of patients with malignant diseases, and these patients have made complete recovery^{7,8,14,15}. The 5-year survival rate of childhood cancer has reached almost 80% and that of acute lymphoblastic leukemia or Hodgkins disease has increased up to 90%¹⁶. Endocrine complications have increased along with improved survival rate of patients. Approximately two thirds of possible complications occurring after transplantation are related to the endocrine system¹⁶. According to previous studies, endocrine complications such as developmental delays, gonadal dysfunction, and thyroid abnormalities were observed after transplantation^{1,16-19}.

In this study, short-term thyroid dysfunction was detected in 27.1% (45 out of 166) of the patients. Among these 45 patients, ESS (64.4%, 29/45 patients) was the most common short-term thyroid dysfunction. ESS was also reported as frequent short-term thyroid dysfunction by Toubert et al.³. A decrease in serum thyroid hormone level in ESS is often seen in stress-inducing conditions, such as starvation, sepsis, surgery, myocardial infarction, bone marrow transplantation, and, in fact, probably any severe illness. It is also called nonthyroidal illness syndrome (NTIS)^{12,13}. With few exceptions, reports indicate that serum T_3 level is low in patients with ESS. Serum T_4 levels are reduced in ESS in proportion to the severity and probably the length of the illness¹³. The degree of alteration of thyroid hormones can predict the outcome in several disease processes^{12,13}. In this study, mortality rate after HSCT was significantly higher in patients with ESS within 3 months during HSCT ($P=0.014$) compared to the non-ESS group. This result showed a close relationship between mortality rate and the incidence of ESS after HSCT. As presented above, ESS represents "hypothyroid state" which is disadvantageous to patients because thyroid hormone plays important role during illness by controlling metabolic rate¹³. Decrease in thyroid hormone could mean a critical damage in ability to overcome serious illness. Thus ESS patients may suffer more from illness and could lead to a worse prognosis. Therefore, ESS patients are more related to mortality rate than those who do not have ESS.

Another study including 80 patients from January 2004 to February 2006 was conducted in the same institute. The most observed short term thyroid dysfunction was ESS but most of them were reported to return to normal after 12 months follow-up. This difference can be explained by the fact that only part of ESS patients (27.5%, 22/80 patients) was followed up for

Table 5. Factors associated with mortality after HSCT

Factor	Univariate logistic regression analysis	
	OR (95% CI)	<i>P</i> value*
Age at HSCT	1.037 (0.967–1.113)	0.309
aGVHD grade		0.080
0–I	1.000	
II–IV	1.861 (0.929–3.730)	
Euthyroid sick syndrome		0.014
No	1.000	
Yes	2.827 (1.239–6.452)	

OR, odds ratio; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; aGVHD, acute graft-versus-host disease.

* $P<0.05$.

Table 6. Risk factors associated with euthyroid sick syndrome during 3 months after HSCT

Factor	Univariate logistic regression analysis	
	OR (95% CI)	<i>P</i> value*
Age at HSCT	1.139 (1.037–1.250)	0.006
Sex		0.632
Male	1.000	
Female	0.632 (0.268–1.488)	
Diagnosis		0.211
Nonmalignant	1.000	
Lymphoid	3.176 (0.793–12.730)	
Myeloid	3.045 (0.836–11.088)	
Conditioning		0.381
Non-TBI based	1.000	
TBI based	1.443 (0.635–3.238)	
aGVHD grade		0.002
0–I	1.000	
II–IV	4.364 (1.736–10.968)	

OR, odds ratio; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; TBI, total body irradiation; aGVHD, acute graft-versus-host disease.

* $P<0.05$.

their thyroid status after 12 months in previously mentioned study. These patients do not represent the whole group. Also, their survival after 12 months has not been discussed in the paper. Therefore, we could conclude that the focus of study was different.

There are 2 hypotheses to explain thyroid hormonal response in ESS: 1) the “hypothyroid” state is a physiologic response to illness that lowers metabolic rate—thereby conserving energy and assisting in recovery—or 2) the “hypothyroid” state is a maladaptive response that impairs tissue function and makes recovery from life threatening illness less likely¹²⁾. In the latter case, thyroid hormone replacement might be beneficial, whereas if the former were true, such treatment would be harmful. Hence, hormone therapy for ESS is controversial¹²⁾. De Groot¹³⁾ reported that T₃ levels in the pituitary are normal because of enhanced local deiodination. Thus, the pituitary is actually euthyroid, whereas the rest of the body is hypothyroid. The patient’s serum and tissue hormone levels are truly low, and this is probably disadvantageous. However, Toubert et al.³⁾ did not carry out any active treatment, because no advantage of thyroid hormone replacement therapy had been found in ESS patients. Moreover, Matsumoto et al.⁶⁾ found that T₃ levels in ESS patients normalized without treatment within 1 year after transplantation. In the present study, ESS patients did not receive thyroid hormone replacement after transplantation as benefits of the replacement are unclear.

While investigating pathogenesis of ESS, researchers have explored a number of possible mediators of ESS in recent years^{12,13)}. One study attempted to investigate the relationship between serum cortisol and T₃ concentrations in patients with hyperpyrexia and ESS. However, administering steroids does not alter ESS in intensive care unit patients¹²⁾. Free fatty acid (FFA), which commonly increases with fasting, stress, and some forms of ESS, can inhibit T₄ binding. It may increase fT₄ and decrease T₄. However, a concentration of FFA in excess of 2 mmol/L is required to induce significant changes in T₄ binding, and that is rarely seen in ESS. On the other hand, McIver and Gorman¹²⁾ explained that interleukin-6 (IL-6) concentrations correlate inversely with T₃ level in a number of ESS states, and IL-6 accounts for up to 30% of T₃ variability. Many studies have also identified tumor necrosis factor alpha (TNF- α) as a reliable mediator that induces the reduction of T₃ and TSH in ESS^{10,12)}.

Subclinical hyperthyroidism was found in 6 out of 45 patients (13.3%) with thyroid dysfunction occurring 3 month after HSCT. Subclinical hyperthyroidism can be associated with ESS, central hypothyroidism, pregnancy and use of drugs, such as steroids. Although additional examination, such as thyrotropin-releasing hormone test, is required to rule out these conditions, we did not carry out such a procedure. Such testing should be enforced after HSCT during following for thyroid function.

Overt hyperthyroidism was detected in 2 patients (4.5%) which is consistent with findings of previous studies. Ishiguro et al.⁹⁾ reported 1 case of overt hyperthyroidism among 147 HSCT patients, and Sanders et al.¹⁴⁾ reported 23 cases of overt hyperthyroidism among 791 HSCT patients.

Only 4 patients (8.9%) showed subclinical hypothyroidism, in contrast to previous reports where subclinical hypothyroidism was the most common complication in patients with long-term thyroid dysfunction after HSCT^{2,9,10)}. This difference could be due to the short-term focus of our study.

We sought to identify risk factors for thyroid dysfunction occurring 3 months after HSCT. Age and acute GVHD grade II or above were significantly associated with this outcome. No such relationship was found for TBI, sex, comorbidity, or type of pre-conditioning regimens. Our analysis of risk factors for ESS within 3 months after HSCT also identified age ($P=0.002$) and acute GVHD of grade II or above ($P=0.009$) as statistically significant. These findings are in keeping with results reported by Vexiau et al.²⁰⁾ who found more thyroid dysfunction in older children after HSCT compared to younger patients (19% vs. 38%). Moreover, Sanders et al.²¹⁾ and Tauchmanova et al.²²⁾ reported that GVHD correlates linearly with endocrine complications in HSCT patients and it confers an adverse prognosis

TBI has been reported to be a risk factor for thyroid dysfunction after HSCT, such as overt hypothyroidism and compensated hypothyroidism^{2,3,5,14,19)}. Sanders et al.¹⁴⁾ and many other studies have reported more long-term thyroid dysfunction detected in patients who received TBI-based preconditioning^{15,17,23)}. However, this was not true in our study, because we focused on short-term thyroid dysfunction.

However, there are some limitations to this study. Although we mainly focused on short term thyroid dysfunction after HSCT in children, long term follow-up could have enabled us to compare our results with previous studies in depth. To overcome this limitation, longer follow-up and further evaluation of their thyroid function needs to be done.

In conclusion, we found that 27.1% of patients experienced thyroid dysfunction during 3 months after HSCT. Univariate analysis identified the relationship between age and acute GVHD of grade II or above with incidence of thyroid dysfunction. Moreover, ESS was found to be related to the mortality rate after HSCT. Thus, short term thyroid function needs to be evaluated after HSCT and any detected thyroid dysfunction should be closely observed for progression into other thyroid abnormalities. Furthermore, continual follow-up examination is crucial to ascertain the recovery of detected thyroid dysfunction.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

- Siekierska-Hellmann M, Babinska A, Oboloneczyk L, Sworczak K, Hellmann A. One-year follow-up of TSH level and thyroid volume in patients with bone marrow or peripheral blood hematopoietic stem cell transplantation following chemotherapy. *Pol Merkur Lekarski* 2007;23:170-3.
- Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillio A, et al. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. *Bone Marrow Transplant* 1995; 15:71-6.
- Toubert ME, Socie G, Gluckman E, Aractingi S, Esperou H, Devergie A, et al. Short- and long-term follow-up of thyroid dysfunction after allogeneic bone marrow transplantation without the use of preparative total body irradiation. *Br J Haematol* 1997;98:453-7.
- Berger C, Le-Gallo B, Donadieu J, Richard O, Devergie A, Galambun C, et al. Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. *Bone Marrow Transplant* 2005;35:991-5.
- Katsanis E, Shapiro RS, Robison LL, Haake RJ, Kim T, Pescovitz OH, et al. Thyroid dysfunction following bone marrow transplantation: long-term follow-up of 80 pediatric patients. *Bone Marrow Transplant* 1990;5:335-40.
- Matsumoto M, Ishiguro H, Tomita Y, Inoue H, Yasuda Y, Shimizu T, et al. Changes in thyroid function after bone marrow transplant in young patients. *Pediatr Int* 2004;46:291-5.
- Sklar CA, Kim TH, Ramsay NK. Thyroid dysfunction among long-term survivors of bone marrow transplantation. *Am J Med* 1982;73:688-94.
- Slatter MA, Gennery AR, Cheetham TD, Bhattacharya A, Crooks BN, Flood TJ, et al. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning. *Bone Marrow Transplant* 2004;33:949-53.
- Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. *J Clin Endocrinol Metab* 2004;89:5981-6.
- Lee SJ, Lee JW, Lee DH, Kwon YJ, Park YS, Hwang HS, et al. Short-term follow up of thyroid function after pediatric hematopoietic stem cell transplantation. *Korean J Pediatr* 2006;49:1211-5.
- Jacobsohn DA. Acute graft-versus-host disease in children. *Bone Marrow Transplant* 2008;41:215-21.
- McIver B, Gorman CA. Euthyroid sick syndrome: an overview. *Thyroid* 1997;7:125-32.
- De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. *J Clin Endocrinol Metab* 1999;84:151-64.
- Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, Storb RF, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. *Blood* 2009; 113:306-8.
- Ricardi U, Corrias A, Einaudi S, Genitori L, Sandri A, di Montezemolo LC, et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. *Int J Radiat Oncol Biol Phys* 2001;50:1287-94.
- Nandagopal R, Laverdiere C, Mulrooney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. *Horm Res* 2008;69:65-74.
- Jung MH, Cho KS, Lee JW, Chung NG, Cho B, Suh BK, et al. Endocrine complications after hematopoietic stem cell transplantation during childhood and adolescence. *J Korean Med Sci* 2009;24:1071-7.
- Sanders JE. Growth and development after hematopoietic cell transplant in children. *Bone Marrow Transplant* 2008;41:223-7.
- Dvorak CC, Gracia CR, Sanders JE, Cheng EY, Baker KS, Pulsipher MA, et al. NCI, NHLBI/PBMTTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. *Biol Blood Marrow Transplant* 2011;17:1725-38.
- Vexiau P, Perez-Castiglioni P, Socie G, Devergie A, Toubert ME, Aractingi S, et al. The 'euthyroid sick syndrome': incidence, risk factors and prognostic value soon after allogeneic bone marrow transplantation. *Br J Haematol* 1993;85:778-82.
- Sanders JE, Woolfrey AE, Carpenter PA, Storer BE, Hoffmeister PA, Deeg HJ, et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. *Blood* 2011;118:1421-8.
- Tauchmanova L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. *Cancer* 2002;95:1076-84.
- Hancock SL, McDougall IR, Constine LS. Thyroid abnormalities after therapeutic external radiation. *Int J Radiat Oncol Biol Phys* 1995;31:1165-70.